Nonalcoholic Fatty Liver Disease (NAFLD)

Author(s): Tatjana Ábel

DOI: 10.2174/9781681084657117010009

Download Download PDF Flyer Cite As
Metabolic Diseases and NAFLD

Pp: 103-118 (16)

Buy Chapters
Add to Cart

* (Excluding Mailing and Handling)

  • * (Excluding Mailing and Handling)

Abstract

SHS investigation development is considered from the geographical and historical viewpoint. 3 stages are described. Within Stage 1 the work was carried out in the Department of the Institute of Chemical Physics in Chernogolovka where the scientific discovery had been made. At Stage 2 the interest to SHS arose in different cities and towns of the former USSR. Within Stage 3 SHS entered the international scene. Now SHS processes and products are being studied in more than 50 countries.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of elevated liver enzymes and chronic liver disease in the Western countries. NAFLD has been noted to be common in patients with obesity, hypertension, type 2 diabetes and atherogenic dyslipidemia. In the United States, it is estimated that NAFLD affects 20-30% of the general population. In patients with diabetes, the prevalence of NAFLD has been reported to be 70%. A high prevalence of NAFLD was found in patients with type 2 diabetes and obesity (90%). NAFLD is an independent predictor of future risk of cardiovascular diseases, and metabolic syndrome as well.

Keywords:

Cardiovascular, Cholesterol, Diabetes, Dyslipidemia, HOMA-IR, Hypertension, Inflammation, Insulin resistance, Lipid disorder, Metabolic syndrome, Obesity, Triglyceride.

Recommended Chapters

We recommend

Favorable 70-S: Investigation Branching Arrow

Authors:Bentham Science Books

Cite as